CYLD and pulmonary arterial hypertension: Pulmonary arterial hypertension (PAH) is a common complication of congenital heart disease (CHD), and CYLD mediates human pulmonary artery smooth muscle cell (HPASMC) dysfunction, which regulates HPASMC phenotypic transformation, proliferation, and migration through modulation of p38 and ERK activation [89].